A Phase 3 Randomized, Open-Label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Next-Generation Hormonal Agent (NHA) and Taxane-Based Chemotherapy

Protocol No
MERCK-MK-5684-003
Staff Member
Kathryn Bylow
Phase
III
Summary

This trial is being done to test the safety of MK-5684, see how well MK-5684 works, compared to abiraterone acetate or enzalutamide, see if participants who get MK-5684 live longer compared to those who get abiraterone acetate or enzalutamide, and see if participants who get MK-5684 live longer before their disease worsens compared to those who get abiraterone acetate or enzalutamide.
Objective
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
Study Sites
Froedtert Hospital
Status
OPEN TO ACCRUAL
Categories
Cancer, Prostate, Prostate and Urologic Cancers
ClinicalTrials.gov
https://www.clinicaltrials.gov/study/NCT06136624